Key result
Targeting coagulation represents a potential therapeutic approach for managing heart failure with preserved ejection fraction and associated cardiac fibrosis.
Key points are not available for this paper at this time.
Should not yet change HFpEF practice; leaves open whether coagulation targeting improves clinical outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hofmann et al. (2019) studied this question. Targeting coagulation represents a potential therapeutic approach for managing heart failure with preserved ejection fraction and associated cardiac fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: